TREANDA Rx

Indications for TREANDA:

Chronic lymphocytic leukemia (CLL). Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Adult:

CLL: Give by IV infusion over 30mins. 100mg/m² on Days 1 and 2 of a 28-day cycle, up to 6 cycles. Hematologic toxicity (≥Grade 3): reduce dose to 50mg/m² on Days 1 and 2 of each cycle; if toxicity recurs, reduce dose to 25mg/m² on Days 1 and 2. Non-hematologic toxicity (clinically significant ≥Grade 3): reduce dose to 50mg/m² on Days 1 and 2 of each cycle. Subsequent cycles: may consider dose re-escalation. NHL: Give by IV infusion over 60mins. 120mg/m² on Days 1 and 2 of a 21-day cycle, up to 8 cycles. Hematologic toxicity (Grade 4) or non-hematologic toxicity (≥Grade 3): reduce dose to 90mg/m² on Days 1 and 2 of each cycle; if toxicity recurs, reduce dose to 60mg/m² on Days 1 and 2. Delay treatment for Grade 4 hematologic toxicity or clinically significant ≥Grade 2 non-hematologic toxicity.

Children:

Not established.

Warnings/Precautions:

Myelosuppression; monitor CBCs including leukocytes, platelets, hemoglobin, neutrophils frequently; restart treatment based on ANC and platelet count recovery. Monitor for signs of infection or reactivation of infections (eg, hepatitis B, CMV, tuberculosis, herpes zoster); prophylaxis and treat prior to therapy if occur. Monitor for infusion or skin reactions, tumor lysis syndrome. Monitor LFTs prior to and during therapy. Renal impairment (CrCl <30mL/min) or moderate-severe hepatic impairment: not recommended. Avoid extravasation. Embryo-fetal toxicity. Pregnancy (Cat.D); avoid during and for 3 months after therapy cessation. Nursing mothers: not recommended.

Pharmacological Class:

Alkylating agent.

Interactions:

May be potentiated CYP1A2 inhibitors (eg, fluvoxamine, ciprofloxacin) or antagonized by CYP1A2 inducers (eg, omeprazole, smoking); if needed, consider alternatives.

Adverse Reactions:

Lymphopenia, anemia, leukopenia, thrombocytopenia, neutropenia, pyrexia, nausea, vomiting, fatigue, diarrhea, constipation, anorexia, cough, headache, weight loss, dyspnea, rash (if severe or progressive, withhold dose or discontinue), stomatitis; infection, infusion reactions (discontinue if severe), tumor lysis syndrome, hepatotoxicity, other malignancies (eg, myelodysplastic syndrome, acute myeloid leukemia, bronchial carcinoma).

Metabolism:

Hepatic (CYP1A2). 94-96% protein bound.

Elimination:

Fecal (90%).

Generic Availability:

NO

How Supplied:

Single-use vial—1